Abstract
Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for MRD, around day-100 post ASCT, 59% were MASS-FIX-positive. At median follow-up of 26 months, 69% of MASS-FIX(+)/NGF(−) patients were alive and progression-free versus 96% of MASS-FIX(-)/NGF(−) patients, P = 0·02. MASS-FIX, a simple peripheral blood-based assay complements marrow-based NGF to accurately prognosticate patients with myeloma.
Original language | English (US) |
---|---|
Pages (from-to) | 380-385 |
Number of pages | 6 |
Journal | British journal of haematology |
Volume | 193 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2021 |
Keywords
- mass spectroscopy
- measurable residual disease
- prognosis
ASJC Scopus subject areas
- Hematology